Abstract
The utility of antibacterials in the management of acute exacerbations of chronic bronchitis (AECB) and the related lung pathology, chronic obstructive pulmonary disease (COPD), has been debated for decades. Data presented in this article document that more expensive antimicrobials may be favored in AECB treatment to prevent adverse outcomes to patients, namely antimicrobial failure and hospitalization. Identified patient-specific variables that may lead to treatment failure include right- or left-sided heart failure and ≥4 exacerbations/year. Risk factors for hospitalization include age ≥65 years and severe pulmonary and nonpulmonary dysfunction. However, these risk factors have never been formally validated in a prospective, randomized trial. Drug-resistant organisms have not been documented to cause antimicrobial failure or hospitalization, however, more data are needed in this growing area.
| Original language | English |
|---|---|
| Pages (from-to) | 333-336 |
| Number of pages | 4 |
| Journal | Disease Management and Health Outcomes |
| Volume | 10 |
| Issue number | 6 |
| State | Published - 2002 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Health Policy
- Nursing(all)
Cite this
Antibacterials and acute exacerbation of chronic bronchitis : Issues for formulary decision makers. / Chock, Alan; Gong, Vera; Destache, Christopher J.
In: Disease Management and Health Outcomes, Vol. 10, No. 6, 2002, p. 333-336.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Antibacterials and acute exacerbation of chronic bronchitis
T2 - Issues for formulary decision makers
AU - Chock, Alan
AU - Gong, Vera
AU - Destache, Christopher J.
PY - 2002
Y1 - 2002
N2 - The utility of antibacterials in the management of acute exacerbations of chronic bronchitis (AECB) and the related lung pathology, chronic obstructive pulmonary disease (COPD), has been debated for decades. Data presented in this article document that more expensive antimicrobials may be favored in AECB treatment to prevent adverse outcomes to patients, namely antimicrobial failure and hospitalization. Identified patient-specific variables that may lead to treatment failure include right- or left-sided heart failure and ≥4 exacerbations/year. Risk factors for hospitalization include age ≥65 years and severe pulmonary and nonpulmonary dysfunction. However, these risk factors have never been formally validated in a prospective, randomized trial. Drug-resistant organisms have not been documented to cause antimicrobial failure or hospitalization, however, more data are needed in this growing area.
AB - The utility of antibacterials in the management of acute exacerbations of chronic bronchitis (AECB) and the related lung pathology, chronic obstructive pulmonary disease (COPD), has been debated for decades. Data presented in this article document that more expensive antimicrobials may be favored in AECB treatment to prevent adverse outcomes to patients, namely antimicrobial failure and hospitalization. Identified patient-specific variables that may lead to treatment failure include right- or left-sided heart failure and ≥4 exacerbations/year. Risk factors for hospitalization include age ≥65 years and severe pulmonary and nonpulmonary dysfunction. However, these risk factors have never been formally validated in a prospective, randomized trial. Drug-resistant organisms have not been documented to cause antimicrobial failure or hospitalization, however, more data are needed in this growing area.
UR - http://www.scopus.com/inward/record.url?scp=0036288560&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036288560&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:0036288560
VL - 10
SP - 333
EP - 336
JO - Disease Management and Health Outcomes
JF - Disease Management and Health Outcomes
SN - 1173-8790
IS - 6
ER -